Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

86
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
86
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

447
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
447
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

546
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
546
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

407
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
407
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

524
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
524
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

85
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
85

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Association between SGLT2 inhibitors and reporting of phimosis/paraphimosis: a comparative pharmacovigilance analysis of the WHO database.

Acta diabetologica·2026
Same author

Comparative atrial fibrillation risk across Bruton's tyrosine kinase inhibitors in B-cell malignancies: A nationwide population-based study.

British journal of haematology·2026
Same author

Applying machine learning to pharmacovigilance data: A proof-of-concept study.

British journal of clinical pharmacology·2026
Same author

Long-term prognosis of patients surviving progressive multifocal leukoencephalopathy.

Brain : a journal of neurology·2026
Same author

Bispecific antibody therapy in multiple myeloma and risk of progressive multifocal leukoencephalopathy.

Blood advances·2026
Same author

Impact of balneotherapy on drug consumption: a systematic review and an economic evaluation of drug deprescribing.

International journal of biometeorology·2026

Related Experiment Video

Updated: Nov 19, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K

Tramadol-induced hypoglycemia: A pharmacovigilance study.

Claire De Canecaude1, Vanessa Rousseau1, Agnès Sommet1

  • 1Service de Pharmacologie Médicale et Clinique, Centre de Pharmacovigilance, de Pharmacoépidémiologie et d'Informations sur le Médicament, CIC INSERM 1436, Faculté de Médecine, Centre Hospitalier Universitaire, Toulouse, France.

Fundamental & Clinical Pharmacology
|January 29, 2021
PubMed
Summary

Tramadol use is linked to an increased risk of hypoglycemia, even when other glucose-lowering drugs are not involved. This study confirms hypoglycemia as a potential adverse drug reaction of tramadol in various patient groups.

Keywords:
analgesicscodeinehypoglycemiatramadol

More Related Videos

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.2K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.6K

Related Experiment Videos

Last Updated: Nov 19, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

5.0K
Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.2K
Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.6K

Area of Science:

  • Pharmacovigilance
  • Drug Safety
  • Clinical Pharmacology

Background:

  • Previous reports suggest tramadol may cause hypoglycemia.
  • Confounding factors, such as co-administered hypoglycemic drugs, complicate previous findings.

Purpose of the Study:

  • To investigate the association between tramadol monotherapy and hypoglycemia using a global pharmacovigilance database.
  • To determine if tramadol is an independent risk factor for hypoglycemia.

Main Methods:

  • Utilized the World Health Organization's VigiBase® pharmacovigilance database for Individual Case Safety Reports (ICSRs) from 2010–2019.
  • Conducted disproportionality analyses, comparing tramadol to codeine, both with and without exclusion of concomitant hypoglycemic drug use.
  • Calculated Reporting Odds Ratios (ROR) with 95% Confidence Intervals (CI) to assess the strength of association.

Main Results:

  • A significant association between tramadol and hypoglycemia reports was observed (ROR = 1.54; 1.43–1.66) before and after excluding cases with other hypoglycemic drugs (ROR = 1.43; 1.31–1.56).
  • Tramadol demonstrated a higher risk of hypoglycemia reports compared to codeine, irrespective of concurrent hypoglycemic medication use.
  • The association was significant in both diabetic and non-diabetic patients.

Conclusions:

  • Hypoglycemia is identified as an adverse drug reaction associated with tramadol use.
  • Tramadol poses a risk for hypoglycemia independent of other hypoglycemic agents.
  • Healthcare providers should be aware of this potential adverse effect when prescribing tramadol.